According to our latest study on “Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End-User,” the market is projected to reach US$ 3,656.38 million by 2028 from US$ 1,909.41 million in 2021; it is expected to grow at a CAGR of 9.7% from 2021 to 2028. The report highlights the key factors driving the market growth and competitive landscape prevalent in the market.
Circulating tumor cells are the seeds for growth and metastases for additional tumors in distant organs and is responsible for majority of cancer related deaths. The diagnosis, detection and analysis of CTC can assist in patients’ prognoses determine appropriate tailored treatments for the patients. The CTC diagnosis has a lot of advantages for traditional diagnostic procedures.
The Circulating Tumor Cell (CTC) Diagnostics market majorly consists of the players such as Thermo Fisher Scientific, StemCell Technologies, Inc, QIAGEN, Precision Medicine Group, LLC, Advanced Cell Diagnostics (Bio-Techne Corporation), Epic Lifesciences, Screencell, Ikonisys, Inc, IVDiagnostics, Fluxion Biosciences among others.
Get Sample PDF Report at :-
Due to the COVID-19 pandemic, the demand for circulating tumor cell (CTC) diagnostics has declined. The unprecedented impact of the pandemic has been far-reaching, but its effects on cancer patients make them one of the worst affected groups. The COVID-19 outbreak has profoundly impacted the patients undergoing cancer screening, diagnosis, and treatment. The increased pressure on hospitals due to the growing hospitalization rate of COVID-19 patients led to the re-profiling of many hospitals and departments, including oncology clinics, for treating COVID-19 patients. In addition, several biotechnology and pharmaceutical companies have shifted their emphasis on developing novel diagnostics and therapies for COVID-19, which has negatively affected the circulating tumor cell (CTC) diagnostics market significantly. Furthermore, many cancer tests and screenings were delayed due to the COVID-19 crisis. At the same time, limited availability of healthcare staff around the world is another factor that negatively impacts the circulating tumor cell diagnostics market
The circulating tumor cell (CTC) diagnostics market is segmented on the basis of technology, application, end user, and geography. Based on technology, the market is segmented into CTC detection and enrichment method, CTC direct detection method, and CTC analysis. Based on application, the circulating tumor cell (CTC) diagnostics market is bifurcated into clinical/liquid biopsy and research. The market for the clinical/liquid biopsy segment is subsegmented into risk assessment, screening, and monitoring. Also, the market for the research segment is further bifurcated into cancer stem cell and tumorigenesis, and drug/therapy development. Based on end user, the circulating tumor cell (CTC) diagnostics market is segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Geographically, the circulating tumor cell (CTC) diagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).
|Dec-2021||Epic Sciences, Inc. announced the launch of DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.|
|July-2021||QIAGEN announced a global strategic alliance with Japan’s Sysmex Corporation for the development and commercialization of cancer companion diagnostics. The alliance aimed to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.|
|Apr-2021||Thermo Fisher Scientific Inc announced the launch of the Thermo Scientific KingFisher Apex Purification System, a high-throughput sample purification instrument designed for scientists who need to automate the extraction of DNA, RNA, proteins and cells from an array of sample types samples such as circulating tumor cells, T-cells and exosomes.|
Thermo Fisher Scientific; Stemcell Technologies, Inc; QIAGEN; Precision Medicine Group, LLC; Advanced Cell Diagnostics (Bio-Techne Corporation); Epic Lifesciences; Screencell; Ikonisys, Inc; IV Diagnostics; and Fluxion Biosciences are a few leading companies operating in the circulating tumor cell (CTC) diagnostics market.
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Healthcare, Media, and Telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, products, applications, end users, etc., which helps our clients to gain a deeper analytical understanding of various research topics.
If you have any queries about this report or would like further information, please contact us:
- North America: +1 646 491 9876
- Asia–Pacific: +91 20 6727 8686
- Email: [email protected]